SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Core Insights - SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, with a live conference call scheduled for November 12, 2024, to report third quarter financial results and discuss business updates [1][2] Company Overview - SpringWorks Therapeutics applies a precision medicine approach to develop life-changing medicines for patients with severe rare diseases and cancer [2] - The company’s first FDA-approved therapy is OGSIVEO® (nirogacestat), which is used for treating adult patients with progressing desmoid tumors requiring systemic treatment [2] - SpringWorks has a diversified pipeline targeting solid tumors and hematological cancers, with programs ranging from preclinical development to advanced clinical trials [2] - The company has established multiple collaborations with industry and academic innovators to enhance its portfolio and create more solutions for patients [2]